VERAXA Biotech (NASDAQ: VRXA) announced that shareholders overwhelmingly approved all proposals presented at its Extraordinary General Meeting, with more than 99.94% of votes cast in favor and 72.20% of the company’s outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030 and an increase in the maximum size of the board of directors from five to seven members.
The company said the enhanced corporate and financing framework is intended to support its long-term growth strategy by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital markets activities and continued development of its BiTAC(R) technology platform and oncology pipeline. Management said the vote reflects strong shareholder support for VERAXA’s strategy of advancing antibody-based cancer therapeutics while pursuing long-term value creation.
The capital band allows the company to raise additional capital within a predefined range without needing further shareholder approval, streamlining future financing efforts. The conditional share capital enables the issuance of shares upon exercise of options and warrants, which can be used to attract and retain talent, fund acquisitions, or support partnerships. Enlarging the board from five to seven members provides room for additional expertise as the company scales its operations.
These governance changes come as VERAXA focuses on its BiTAC (bispecific T cell engager) technology and other antibody-based therapeutics. The company is building a pipeline of next-generation cancer treatments, including bispecific ADCs and other innovative formats, powered by transformative technologies and quality-by-design principles. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution.
The strong approval, with over 99.94% of votes in favor, signals shareholder confidence in the company’s direction. The high turnout of 72.20% of outstanding shares indicates active investor engagement. For the industry, the adoption of flexible capital structures is becoming more common as biotech firms seek to navigate the capital-intensive drug development process. The ability to quickly access capital and adjust governance can be critical for advancing clinical programs and securing partnerships.
For investors, these measures reduce the need for frequent special meetings for financing approvals and may accelerate decision-making. However, they also introduce potential dilution if options or warrants are exercised. The company’s forward-looking statements highlight risks including those detailed in its SEC filings, such as in the Annual Report on Form 10-K and quarterly reports. The full press release is available at https://ibn.fm/qfL87, and updates can be found in the company’s newsroom at https://ibn.fm/VRXA.
